Autoantibody biomarkers for the detection of serous ovarian cancer

Benjamin A. Katchman, Diego Chowell, Garrick Wallstrom, Allison F. Vitonis, Joshua LaBaer, Daniel W. Cramer, Karen Anderson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. Methods To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n = 30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n = 30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n = 63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95% specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed. Results We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity. Conclusion These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalGynecologic Oncology
Volume146
Issue number1
DOIs
StatePublished - Jul 1 2017

Fingerprint

Autoantibodies
Ovarian Neoplasms
Biomarkers
Neoplasm Antigens
Serum
Pro-Opiomelanocortin
Protein Array Analysis
Autoantigens
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Antigens
Neoplasms

Keywords

  • Autoantibody
  • Biomarker
  • Diagnostics
  • Ovarian cancer
  • Proteomics

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Autoantibody biomarkers for the detection of serous ovarian cancer. / Katchman, Benjamin A.; Chowell, Diego; Wallstrom, Garrick; Vitonis, Allison F.; LaBaer, Joshua; Cramer, Daniel W.; Anderson, Karen.

In: Gynecologic Oncology, Vol. 146, No. 1, 01.07.2017, p. 129-136.

Research output: Contribution to journalArticle

Katchman, BA, Chowell, D, Wallstrom, G, Vitonis, AF, LaBaer, J, Cramer, DW & Anderson, K 2017, 'Autoantibody biomarkers for the detection of serous ovarian cancer', Gynecologic Oncology, vol. 146, no. 1, pp. 129-136. https://doi.org/10.1016/j.ygyno.2017.04.005
Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW et al. Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecologic Oncology. 2017 Jul 1;146(1):129-136. https://doi.org/10.1016/j.ygyno.2017.04.005
Katchman, Benjamin A. ; Chowell, Diego ; Wallstrom, Garrick ; Vitonis, Allison F. ; LaBaer, Joshua ; Cramer, Daniel W. ; Anderson, Karen. / Autoantibody biomarkers for the detection of serous ovarian cancer. In: Gynecologic Oncology. 2017 ; Vol. 146, No. 1. pp. 129-136.
@article{d60bf475a7664e4b9749ce3cad4abb38,
title = "Autoantibody biomarkers for the detection of serous ovarian cancer",
abstract = "Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. Methods To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n = 30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n = 30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n = 63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95{\%} specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed. Results We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45{\%} sensitivity at 98{\%} specificity. Conclusion These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.",
keywords = "Autoantibody, Biomarker, Diagnostics, Ovarian cancer, Proteomics",
author = "Katchman, {Benjamin A.} and Diego Chowell and Garrick Wallstrom and Vitonis, {Allison F.} and Joshua LaBaer and Cramer, {Daniel W.} and Karen Anderson",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.ygyno.2017.04.005",
language = "English (US)",
volume = "146",
pages = "129--136",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Autoantibody biomarkers for the detection of serous ovarian cancer

AU - Katchman, Benjamin A.

AU - Chowell, Diego

AU - Wallstrom, Garrick

AU - Vitonis, Allison F.

AU - LaBaer, Joshua

AU - Cramer, Daniel W.

AU - Anderson, Karen

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. Methods To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n = 30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n = 30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n = 63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95% specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed. Results We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity. Conclusion These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.

AB - Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. Methods To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n = 30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n = 30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n = 63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95% specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed. Results We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity. Conclusion These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.

KW - Autoantibody

KW - Biomarker

KW - Diagnostics

KW - Ovarian cancer

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85017567816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017567816&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.04.005

DO - 10.1016/j.ygyno.2017.04.005

M3 - Article

VL - 146

SP - 129

EP - 136

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -